Abstract The United States Food and Drug Administration (US FDA) has always been a
forerunner in drug evaluation and supervision. Over the past 31 years, 1050 drugs …

Despite tremendous gains in the molecular understanding of exocrine pancreatic cancer,
the prognosis for this disease remains very poor, largely because of delayed disease …

Background The primary analysis of the phase 3 NETTER-1 trial showed significant
improvement in progression-free survival with 177 Lu-Dotatate plus long-acting octreotide …

Abstract Purpose of Review The purpose of our review is to explore global epidemiologic
trends of gastroenteropancreatic (GEP) neuroendocrine tumors (NETs). Specifically, we …

Importance Although the incidence and prevalence of gastroenteropancreatic
neuroendocrine tumors (GEP-NETs) have been thought to have increased during the past …

Gastrointestinal neuroendocrine tumors are rare slow-growing tumors with distinct
histological, biological, and clinical characteristics that have increased in incidence and …

This review aimed to analyze the scientific literature on pancreatic diseases (especially
exocrine pancreatic insufficiency). This review also describes the correlation between the …

Simple Summary Neuroendocrine neoplasms are divided into two groups: well-
differentiated neuroendocrine tumors and poorly differentiated neuroendocrine carcinomas …

Abstract The American Joint Committee on Cancer (AJCC) staging system for all cancer
sites, including gastroenteropancreatic neuroendocrine tumors (GEP‐NETs), is meant to be …

Neuroendocrine tumors (NETs) include a heterogeneous group of malignancies arising in
the diffuse neuroendocrine system and characterized by indolent growth. Complex …